Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 9, 2025

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help …

Dentsply Sirona to Host First Quarter Conference Call on May 8th

Dentsply Sirona to Host First Quarter Conference Call on May 8th

CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am …

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the …

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

KSQ Therapeutics Announces First Patient Dosed in Phase 1/2 Study for KSQ-004EX, a CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

LEXINGTON, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid tumors, today announced the first patient dosed in the Phase 1/2 clinical study of KSQ-004EX, a novel …

Microbix Exhibiting at ESCMID Global 2025

Microbix Exhibiting at ESCMID Global 2025

MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending and exhibiting at ESCMID Global 2025 and that …

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. …

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST                    Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday, 23 April 2025 at …

Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025

Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025

ORION OYJ                 LEHDISTÖTIEDOTE 9.4.2025 KLO 13.30          Orion julkaisee osavuosikatsauksen 1–3/2025 ja järjestää verkkolähetyksen 23.4.2025 Orion julkaisee osavuosikatsauksen 1–3/2025 keskiviikkona 23.4.2025 noin klo 12.00. Tiedote ja siihen …

Coave Therapeutics to Attend Upcoming Conferences

Coave Therapeutics to Attend Upcoming Conferences

Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following industry conferences: Cell …

برنامج "مسيرة المرأة الإماراتية" يرحب ب 62 منتسبة جديدة للمشاركة في الدفعة الثانية

برنامج "مسيرة المرأة الإماراتية" يرحب ب 62 منتسبة جديدة للمشاركة في الدفعة الثانية

أبوظبي، الإمارات العربية , April 09, 2025 (GLOBE NEWSWIRE) --  تحت رعاية سموّ الشيخة فاطمة بنت مبارك، رئيسة الاتحاد النسائي العام، رئيسة المجلس الأعلى للأمومة والطفولة، الرئيسة الأعلى لمؤسَّسة التنمية الأسرية "أم الإمارات"، وبالتعاون مع الاتحاد النسائي …

Emirati Women Chapter Onboards Second Cohort of 62 Participants

Emirati Women Chapter Onboards Second Cohort of 62 Participants

ABU DHABI, United Arab Emirates, April 09, 2025 (GLOBE NEWSWIRE) -- Under the patronage of Her Highness Sheikha Fatima bint Mubarak, Chairwoman of the General Women's Union (GWU), President of the Supreme Council for Motherhood and Childhood (SCMC), …

Barbara Weber, M.D., Elected to ITM Supervisory Board

Barbara Weber, M.D., Elected to ITM Supervisory Board

Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election …

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer

Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of Medicine at the University of Maryland …

Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development

Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development

First-ever use of Ebenbuild’s Twinhale technology  in idiopathic pulmonary fibrosis lung models Trial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of …

SBC Medical to Present at the Emerging Growth Conference on April 17, 2025

SBC Medical to Present at the Emerging Growth Conference on April 17, 2025

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, is pleased to announce that it has been invited to …

Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer

Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer

ZURICH, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, a leading biotech company in single-cell manipulation and cell engineering solutions, announces the appointment of Magid Haddouchi, PhD, as its new Chief Commercial Officer (CCO), …

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO

HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its Chief Executive Officer (CEO …

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation highlights new insights in genital …

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – …

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025

OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à long terme de l’anticorps monoclonal …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service